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878Low to Moderate Dose Anthracycline-Based Chemotherapy
Is Associated With
Early Noninvasive Imaging Evidence of
Subclinical Cardiovascular DiseaseOBJECTIVES The goal of this study was to determine if low to moderate doses of anthracycline-based
chemotherapy (Anth-bC) are associated with subclinical cardiovascular (CV) injury.
BACKGROUND Cancer survivors who receive Anth-bC experience premature CV events. It is unknownwhether
low to moderate doses of anthracyclines promote early subclinical CV disease manifested by deteriorations in left
ventricular ejection fraction (LVEF) or increases in aortic stiffness, or if these doses are associated with changes in
quality of life (QOL).
METHODS In 53 men and women with breast cancer, leukemia, or lymphoma, we assessed left ventricular
volumes, LVEF, circumferential strain, aortic pulse wave velocity, late gadolinium enhancement, serum B-type
natriuretic peptide, troponin I, and the impact of treatment on QOL before and 1, 3, and 6 months after
receipt of Anth-bC.
RESULTS Participants averaged 50  2 (range 19 to 80) years in age, 58% were women, 17% were black, and
they each received a range of 50 to 375 mg/m2 of doxorubicin-equivalent chemotherapy. Left ventricular end-
systolic volume (48  3 ml to 54  3 ml; p ¼ 0.02), left ventricular strain (–17.7  0.4 to –15.1  0.4; p ¼
0.0003), pulse wave velocity (6.7  0.5 m/s to 10.1  1 m/s; p ¼ 0.0006), and QOL deterioration (15.4  3.3 to
28.5  3.9; p ¼ 0.008) increased, whereas LVEF (58  1% to 53  1%; p ¼ 0.0002) decreased within 6 months
after low to moderate doses of Anth-bC. All ﬁndings persisted after accounting for age, gender, race (white/
black), doxorubicin-equivalent dose, doxorubicin administration technique, comorbidities associated with CV
events, and cancer diagnosis (p ¼ 0.02 to 0.0001 for all). There were no new late gadolinium enhancement
ﬁndings after 6 months.
CONCLUSIONS In these study patients, low to moderate doses of Anth-bC were associated with the early
development of subclinical abnormalities of cardiac and vascular function that in other populations are
associated with the future occurrence of CV events. (J Am Coll Cardiol Img 2013;6:877–85) ª 2013 by the
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879lthough anthracycline-based chemothera-
peutic regimens for breast and hematologic
malignancies have improved cancer-related
survival, studies have recognized an unan-
ticipated increase in premature cardiovascular (CV)
events among individuals receiving these regimens
(1–4). Today, CV events including systolic or dia-
stolic left ventricular dysfunction, congestive heart
failure, stroke, and myocardial ischemia and infarc-
tion are the second leading cause of premature
morbidity and mortality among those surviving
>5 years after their initial diagnosis and treatment forSee page 886
A B B R E V I A T I O N S
A N D A C R O N YM S
Anth-bC = anthracycline-based
chemotherapy
BNP = B-type natriuretic peptide
CMR = cardiac magnetic
resonance
CV = cardiovascular
MLHFQ = Minnesota Living with
Heart Failure Questionnaire
LVEDV = left ventricular
end-diastolic volume
LVEF = left ventricular
ejection fraction
LVESV = left ventricular
end-systolic volume
PWV = pulse wave velocity
QOL = quality of life
TE = echo time
TnI = troponin I
TR = repetition timebreast cancer (2), Hodgkin disease, or non-Hodgkin
lymphoma (3,4). Currently, anthracycline-based
chemotherapeutic agents are typically limited to cu-
mulative doses#450 mg/m2 to reduce the incidence
of clinical CV events (5), but to date, studies have
not addressed whether lower doses of anthracyclines
administered in the course of cancer treatment could
promote early subclinical CV injury that in other
populations (e.g., those with hypertension or
atherosclerosis) are associated with future CV events.
Accordingly, we hypothesized that the adminis-
tration of low to moderate doses of anthracycline-
based chemotherapy (Anth-bC) would be associated
with the early onset of subclinical CV disease that in
other populations is associated with future CV
events. To address this hypothesis, we measured
imaging, biochemical, and quality of life (QOL)
markers that have been used in other, larger
population-based studies to identify subclinical
CV disease predictive of adverse CV outcomes. We
performed these measurements in a cohort of sub-
jects recently diagnosed with either breast cancer or a
hematologic malignancy who were scheduled to
receive low to moderate doses of Anth-bC for the
ﬁrst time.
METHODS
Study population and design. This study was
approved by the institutional review board of the
Wake Forest School of Medicine and was funded by
the National Cancer Institute (R33CA12196). All
participants provided witnessed, written informed
consent. The study population consisted of 53 par-
ticipants who were scheduled to receive Anth-bC for
the ﬁrst time. They were consecutively recruited over
a 1.5 year period from the hematology/oncology
outpatient clinics and inpatient hospital facilities
within the Comprehensive Cancer Center at WakeForest School of Medicine. Participants were asked
to identify their race/ethnicity when enrolled in the
study and this data was utilized as a variable in
reporting participant demographic characteristics.
Cardiac magnetic resonance (CMR), serum bio-
markers, and questionnaires assessing quality of life
(QOL) were performed according to speciﬁcations
used in other large National Institutes of Health
sponsored population based studies of CV disease
such as MESA (Multi-Ethnic Study of Athero-
sclerosis) (6). These markers were acquired before
cancer treatment, and at 1, 3, and 6 months after
initiation of low to moderately dosed Anth-bC. The
1, 3, and 6 month CMR imaging and serum
biomarker acquisitions were obtained early each
morning prior to the scheduled administration of
chemotherapy. Analyses of all images were
performed by individuals blinded to all
study participant identiﬁers, including
previous imaging and biomarker results
(i.e., a blinded, unpaired read). Participants
were ineligible for enrollment if they had a
contraindication to CMR (implanted metal
or electronic devices). No participants
received radiation therapy during the study.
CMR technique and measurements.
DETERMINATION OF LEFT VENTRICULAR
VOLUMES AND EJECTION FRACTION. All
participants underwent scanning using a
1.5-TMagnetomAvantoScanner (Siemens,
Erlangen, Germany). Left ventricular
volumes and left ventricular ejection fraction
(LVEF) were measured according to previ-
ously published methods (7) by using cine
white blood steady-state free precession
techniques with a 256 128matrix, a 40-cm
ﬁeld of view, a 10-ms repetition time (TR), a
4-ms echo time (TE), a 20-degree ﬂip
angle, a slice 8-mm thick, and a 40-ms temporal
resolution. Ventricular volumes were also indexed to
body surface area.
LEFT VENTRICULAR CIRCUMFERENTIAL STRAIN.
Strain imaging was performed according to
previously published methods using the spatial
modulation of magnetization technique at the
middle papillary muscle level of the left ventricular
short axis as identiﬁed on the 4-chamber view (8).
Imaging parameters included a 34-cm ﬁeld of
view, a 10-ms TR, a 4-ms TE, a 20-degree ﬂip
angle, a slice 8-mm thick, a 256  160 matrix, and a
32-kHz bandwidth. Mean mid-wall left ventricular
circumferential strain was measured according to
previously published methods using harmonic phase
Table 1. Demographic Data (N [ 53)
Age, yrs 50  2
Women 58
Height, cm 170  2
Weight, kg 84  3
Body mass index, kg/m2 29.6  1.6
Race, white/black 83/17
Cardiovascular risk factors
Coronary artery disease 8
Diabetes 13
Hypertension 40
Hyperlipidemia 25
Smoking 45
Medications
Beta-blocker 17
Calcium antagonist 8
Angiotensin-converting enzyme inhibitor 26
Angiotensin receptor blocker 6
Vasodilator 4
Statin 21
Diuretic 26
Values are mean  SE or %.
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880analyses (HARP, Diagnosoft, Inc., Cary, North
Carolina) (9).
Aortic stiffness. Thoracic aortic pulse wave velocity
(PWV) was determined according to previously
published methods (6,10). Phase-contrast CMR im-
aging parameters included a 34- to 36-cm ﬁeld of
view, a 256 912matrix, a 6-msTR, a 3- to 5-msTE,
a 15- to 20-degree ﬂip angle, a slice 8-mm thick,
through-plane velocity encoding of 150 cm/s, tem-
poral resolution of 25 to 35 ms, GRAPPA accelera-
tion factor of 2, and 4 to 8 lines of K-space
segmentation with 30 frames reconstructed. The
distance between ascending and descending thoracic
aorta was obtained by tracing the centerline of the
aortic lumen on a sagittal localizing image. The transit
time of the ﬂow wave was determined as the time
delay between the ascending and descending aortic
waveforms at 50% of their respective peaks (10).
Late gadolinium enhancement. Late gadolinium
enhancement imaging was performed according to
previously published methods (11). Inversion time
sequences were performed 10 min after gadolinium
injection, with an inversion time to provide a uni-
formly dark noninfarcted myocardium. Multislice
short-axis inversion recovery late gadolinium en-
hancement images were obtained scanning the heart
base to the left ventricular apex. Scan parameters
included a 784-ms TR, a 3.3-ms TE, a 130-Hzbandwidth, 36 cm ﬁeld of view, and 317  390
matrix.
Serum B-type natriuretic peptide and troponin-I. At
each study visit, patients underwent venipuncture for
blood sampling, which was performed before receipt
of chemotherapy. Serum troponin-I (TnI) (Beckman
Coulter Inc., Brea, California) and B-type natriuretic
peptide (BNP) (Phoenix Pharmaceuticals, Inc.,
Burlingame, California) levels were assessed ac-
cording to previously published methods (12,13).
Serum TnI values #0.06 ng/ml were considered
negative for myocardial injury; values of 0.06 # x
<1.0 ng/ml were considered subclinical, and values
$1.0 ng/ml were considered as a clinical injury (14).
Impact on QOL. At each study visit, patients
completed the Minnesota Living with Heart Failure
Questionnaire (MLHFQ) to assess the impact of
cancer treatment on their QOL (15). This well-
established questionnaire contains 21 items that
assess key areas of physical, emotional, social, and
mental dimensions of QOL. Respondents rate each
item on a 6-point Likert scale ranging from 0 ¼ no
impact to 5 ¼ very much of an impact.
Statistical analysis. Descriptive statistics, including
mean SEs for continuous measures and counts and
percentages for categorical measures, were calculated
for the study participants. A series of repeated mea-
sures mixed models were then ﬁt to examine the
impact of time on the outcomes of interest; partici-
pants in these models were treated as random effects.
Time was entered into the models as a random effect
and considered as a continuous, time-varying mea-
sure. A series of pre-deﬁned covariates were assessed
to determine whether the time effect on the outcome
of interest was affected by the covariate. To do this,
time by covariate interactions were ﬁt separately for
each covariate. These covariates included age, race,
gender, doxorubicin-equivalent chemotherapy dose
(16), type of cancer, the number of CV risk factors
present at baseline (e.g., hypertension, diabetes,
hyperlipidemia, tobacco use, history of myocardial
infarction or revascularization), and associated
chemotherapy (deﬁned as cyclophosphamide, tras-
tuzumab, or all other agents). If the time by risk
factor interaction was not signiﬁcant, then mixed
models were ﬁt including only the main effects for
time and the risk factor. In particular, for left ven-
tricular volumes, PWV, and strain, in which differ-
ences between men and women were expected, we
examined whether the time effects were consistent
for men and women.
All analyses were performed by personnel within
the Department of Biostatistics in the Wake Forest
School of Medicine using SAS version 9.2 (SAS
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Figure 1. Time-Dependent Changes in Left Ventricular Parameters
Time-dependent changes in left ventricular end-diastolic volume (left y-axis; A), left ven-
tricular end-systolic volume (LVESV) (right y-axis; A), left ventricular ejection fraction (LVEF)
(left y-axis; B), and mean mid-wall circumferential strain (right y-axis; B). The values are
given as mean  SE. There was a signiﬁcant increase in LVESV and mean mid-wall
circumferential strain while, at the same time, there was a decrease in LVEF from baseline to
6 months after administration of low to moderate doses of anthracycline-based
chemotherapy.
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881Institute, Inc., Cary, North Carolina); p values
#0.05 were considered signiﬁcant.
RESULTS
Demographic data from the 53 participants are dis-
played in Table 1. Their mean age was 50  2 years
(range 19 to 80 years). The majority of participants
were women (58%) and of white race (83%). Four
participants had known pre-existing coronary artery
disease with previous revascularization. Overall,
42%, 32%, 24%, and 2% of the participants had been
diagnosed with breast cancer, lymphoma, leukemia,
and myelodysplastic syndrome, respectively.
Doxorubicin was administered to 37 participants
(240 mg/m2 median cumulative dose; range 50 to
375 mg/m2) and daunorubicin to 16 participants
(180 mg/m2 median cumulative dose; range 36 to
500 mg/m2). The anthracycline doxorubicin-
equivalent doses for all participants ranged from
50 to 375 mg/m2. The majority of participants
(92%) received the anthracycline as a 15-min
intravenous infusion during consecutive days. The
remaining 4 participants received the anthracycline
as a 24-h intravenous infusion as part of their
chemotherapy regimen.
Left ventricular end-diastolic volume (LVEDV)
remained similar (113  5 ml at baseline and 114 
5 ml at study end) throughout the study (p ¼ 0.2)
(Fig. 1A). Left ventricular end-systolic volume
(LVESV) increased from 48  3 ml to 54  3 ml
(p ¼ 0.02) during the study. As a result of these
changes in left ventricular volumes, LVEF dimin-
ished (from 58  1% to 53  1% [p ¼ 0.0002])
(Fig. 1B) over 6 months. At baseline, 11% of the
cohort (n ¼ 6) exhibited an LVEF <50%, but
this increased to 34% after completion of Anth-bC
(p ¼ 0.002). Of the 47 participants who had an
LVEF >50% at baseline, 26% experienced a LVEF
of <50% (a metric used clinically to distinguish
mildly impaired left ventricular systolic dysfunction)
6 months after receipt of Anth-bC (p < 0.01). The
decline in LVEF also paralleled a 6-month increase
in left ventricular mean mid-wall circumferential
strain (less negative values reﬂect worsening regional
systolic function [17.7  0.4 to 15.1  0.4;
p ¼ 0.0003] [Fig. 1B]).
PWV increased steadily from 6.7  0.5 m/sec to
10.1  1.0 m/s (p ¼ 0.0006) after Anth-bC
administration (Fig. 2). Adjusting for baseline
heart rate had a minimal impact on the change in
PWV over time. However, after adjusting for
baseline systolic blood pressure in a ﬁtted model,
participants with a higher systolic blood pressurehad a higher PWV at baseline, in addition to a
faster increase in PWV, over time compared
with participants with lower systolic blood pressure
(p ¼ 0.036).
Three participants with previous myocardial
infarction and revascularization had late gadolinium
enhancement imaging consistent with myocardial
scar. Results of all other baseline and 6-month late
gadolinium enhancement studies were unremark-
able. Serum BNP did not increase and trended (p ¼
0.2) toward a decrease throughout the study (63 
14 pg/ml at baseline and 46  4 pg/ml at study
end). Serum TnI averaged 0.02  0.003 ng/ml at
baseline and 0.04  0.01 ng/ml at the 6-month
Figure 3. Time-Dependent Changes in QOL
Quality of life (QOL) was assessed using the Minnesota Living with
Heart Failure Questionnaire (MLHFQ). The total point mean  SE
values are shown. There was a signiﬁcant increase in the total
score, indicating a negative impact on QOL, from baseline to
1 month after administration of low to moderate doses of
anthracycline-based chemotherapy, which was maintained
through 6 months.
Figure 2. Time-Dependent Changes in Pulse Wave Velocity
The values are given as mean  SE. There was a signiﬁcant
increase in pulse wave velocity from baseline to 6 months after
administration of low to moderate doses of anthracycline-based
chemotherapy.
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882visit (p ¼ 0.12). More importantly, 26% of the
cohort exhibited evidence of subclinical cardiac
injury (0.06 < TnI #1.0) on the morning before
their ﬁnal dose of anthracycline.
The negative impact of low to moderate Anth-bC
on QOL signiﬁcantly increased over time (p ¼
0.008). Mean score on the MLHFQ was 15.4  3.3
at baseline, 27.8  3.5 after treatment, and 28.5 
3.9 at study end (Fig. 3). The change observed in
QOL trended toward a positive association with the
change in LVEF (r ¼ 0.085) and myocardial strain
(r ¼ 0.24), but neither was found to be statistically
signiﬁcant (p ¼ 0.64 and 0.17, respectively).
Measures of LVESV, LVEF, left ventricular
strain, PWV, and QOL remained different at the
6-month visit relative to baseline values after ac-
counting for CV risk factors regardless of the
number of comorbid conditions experienced by a
participant (p ¼ 0.02 to 0.0001 for all) and after
accounting for the presence of baseline late gado-
linium enhancement imaging (p ¼ 0.02 to 0.0001).
Abnormal trends in these parameters (LVESV,
LVEF, left ventricular strain, PWV, and QOL) also
persisted at the end of the study relative to baseline
after adjusting for race only (p ¼ 0.02 to 0.0002 for
all), gender only (p ¼ 0.015 to 0.0001 for all),
cancer diagnosis only (p ¼ 0.018 to 0.0002 for all),
anthracycline administration protocol only (p ¼
0.02 to 0.0002 for all), and in a model that adjusted
for gender, age, race, and doxorubicin-equivalent
cumulative dose (p ¼ 0.016 to 0.0001 for all).
The cumulative doses of doxorubicin-equivalent
chemotherapy administered in this study did notcorrelate with greater reductions in LVEF or in-
creases in PWV (Fig. 4). This ﬁnding was similar
for myocardial strain (p ¼ 0.12). Thirty-nine par-
ticipants (74%) received cyclophosphamide. The
addition of cyclophosphamide, trastuzumab, or all
other adjuvant chemotherapy agents in combination
with anthracyclines was not associated with larger
decrements in LVEF or increases in PWV or strain.
D I SCUSS ION
Our results demonstrate 5 important ﬁndings. First,
measures of left ventricular systolic performance
(LVESV, LVEF, and mean mid-wall circumfer-
ential strain) deteriorated early and remained
abnormal 6 months after initiation of low to mod-
erate doses of Anth-bC (Fig. 1). Second, partici-
pants exhibited an increase in PWV (a measure of
aortic stiffening), which occurred early during the
ﬁrst 6 months after initiation of low to moderate
doses of Anth-bC (Fig. 2). Third, we did not detect
new infarcts or ﬁbrosis by late gadolinium
enhancement that were commensurate with the
other subclinical abnormalities that occurred during
the 6 months of receipt of Anth-bC. Fourth, these
changes in subclinical abnormalities of cardiac and
vascular function occurred in parallel with wors-
ening effects on physical, emotional, social, and
mental dimensions of QOL (Fig. 3), but due to our
small sample size, we did not appreciate a signiﬁcant
association between CV function and QOL.
Finally, the magnitude of subclinical deterioration
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Figure 4. Cumulative Doxorubicin Dose Effect on Cardiac and Vascular Function
Changes in left ventricular ejection fraction (y-axis; A) and pulse wave velocity (y-axis; B)
versus the cumulative doses of doxorubicin-equivalent chemotherapy (x-axes; A and B).
Each symbol represents data from a participant, and the regression line and equations are
shown for each panel. No association between changes in left ventricular ejection fraction
or pulse wave velocity and the doses of doxorubicin-equivalent chemotherapy were
observed.
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 6 , N O . 8 , 2 0 1 3 Drafts et al.
A U G U S T 2 0 1 3 : 8 7 7 – 8 5 Anthracyclines and Subclinical CVD
883in cardiac and vascular function is not correlated
with the total amount of anthracycline received after
treatment for cancer (Fig. 4).
In the 1970s, investigators recognized that rela-
tively high doses (>500 mg/m2) of anthracyclines
were associated with increases in morbidity and
mortality related to overt clinical heart failure (4).
Over the past 10 years, premature CV events have
emerged in long-term survivors of adult and pedi-
atric lymphoma and leukemia and in women with
breast cancer (2–4). Individuals in our study were
not exposed to high doses but rather to low/mod-
erate doses of Anth-bC. Our results suggest that
early during the exposure to these low doses, in-
dividuals develop subclinical abnormalities of both
left ventricular performance and aortic stiffness.
Three metrics of left ventricular systolic function
(LVESV, LVEF, and strain) deteriorated over the
course of the study. Changes similar to these (2- to
6-ml increase in LVESV or a 5% drop from a normal
resting LVEF) were associated with an adverse CV
prognosis in a study of patients with heart failure and
a preserved resting LVEF (17). Importantly, within
6 months of the receipt of chemotherapy, 26% of
individuals who exhibited an LVEF >50% at
baseline experienced a deterioration in LVEF
<50%, a threshold that identiﬁes abnormal left
ventricular performance which often warrants initi-
ation of medical therapy (18,19). Of note, LVEDV
did not decrease during the current study; thus, the
changes we observed in LVEF and mid-wall
myocardial strain were not due to decreases in left
ventricular preload that occasionally occur with
decreased oral intake or vomiting during receipt of
anthracyclines.
Echocardiographically, changes in mid-wall
myocardial strain have been shown to deteriorate
before changes in left ventricular fractional short-
ening or LVEF in individuals receiving moderate to
high doses of Anth-bC (20,21). In this study,
myocardial strain diminished early, commensurate
with a decrement in LVEF. The difference in our
results could be explained by the heightened accu-
racy of CMR in measuring left ventricular volumes
and LVEF (22). After multivariable analyses, the
subclinical abnormalities we observed in LVESV,
LVEF, and mid-wall circumferential strain occurred
regardless of gender, race, associated CV comor-
bidities, or the total amount of Anth-bC received.
Of note, our mid-wall, mean circumferential strain
short-axis image acquisitions were similar to those
performed in MESA (7) and have prognostic value
for both CV events and left ventricular remodeling
after myocardial infarction (23). Future studiescould consider the addition of longitudinal strain
measures acquired from left ventricular apical views
that have been found useful clinically during trans-
thoracic echocardiography.
Anth-bC was associated with an early and
persistent increase in PWV, a measure of vascular
stiffening that is associated with increased left
ventricular afterload, left ventricular dysfunction
and hypertrophy, and adverse CV events, including
mortality (24,25). The average change in PWV of
>3 m/s to a mean value of 10.1  1.0 m/s that we
observed in the current study has been found clinically
relevant in other patient populations. In a study of
483 hypertensive patients with a mean age of 50 13
years, aortic PWV measure of 11.5  3.4 m/s was
associatedwith an odds ratio of 2.14 for cardiac events
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884(p < 0.0001) (25). The rapid (1-month) increase in
PWV suggests that an acute (endothelial dysfunc-
tion, increase in smooth muscle tone) rather than
chronic (atherosclerosis, increased collagen synthesis)
process inﬂuenced aortic stiffening in our participants
(10); however at this time, we are uncertain of the
mechanism of this stiffening.
Although late gadolinium enhancement imaging
exhibits diagnostic and prognostic utility in multiple
CV disorders (26), its use in assessment of the
effects of Anth-bC is limited to 1 case series of
2 patients with Ewing’s sarcoma who developed
subendocardial enhancement >10 years after receipt
of an anthracycline (27). Our results demonstrated
no new late gadolinium enhancement during receipt
of low doses of Anth-bC at a time when other
subclinical functional CV abnormalities occurred.
Serum TnI levels demonstrated an upward
trend 6 months after initiation of Anth-bC, and
26% of the participants met the criteria (0.06 #
x <1.0 mg/ml) for subclinical CV injury 3 months
into treatment with Anth-bC. Previously, in-
vestigators demonstrated an association between
similar subclinical elevations of serum TnI and
future cardiac events in individuals treated with
chemotherapy (28). It is also important to note that
serum BNP did not increase during the duration of
this study, which reﬂects that participants were not
in clinical decompensated heart failure. This ﬁnding
suggests that BNP does not contribute to the
screening of subclinical CV disease in this patient
population.
In addition to CV structural and functional
changes seen with low- to moderate-dose Anth-bC,
there were also negative changes in QOL that
involved physical, emotional, social, and mental
aspects. These changes were signiﬁcant early after
receipt of chemotherapy and remained signiﬁcant at
6 months. A recent study has validated the
MLHFQ and reported that an increase of 5 total
points is clinically signiﬁcant (29).
Those treated for breast cancer or a hematologic
malignancy, or those receiving doxorubicin versus
daunorubicin, experienced similar increases in PWV
and decreases in left ventricular performance. It is
noteworthy that there was no correlation between
the decrease in LVEF, or the increase in PWV, and
the cumulative dose of doxorubicin-equivalent
chemotherapy administered to participants in the
study. In addition, our resting measures of LVEF
(57.9  1.0%) and PWV (6.7  0.5 m/s) are similar
to measures observed in other populations withoutclinical CV disease (25,30,31); thus, we did not
appreciate a resting abnormality of CV function that
would necessarily contribute to our results.
Study limitations. First, although the high accuracy
and reproducibility of CMR allowed us to identify
subclinical abnormalities of CV function in patients
receiving treatment for cancer with a small sample
size, studies with larger numbers of participants
could identify whether speciﬁc CV risk factors pre-
dispose individuals to develop early subclinical CV
injury on receipt of Anth-bC. Second, there were no
Hispanic or Asian participants in the study. For this
reason, we are unable to derive conclusions regarding
the relationship between anthracycline administra-
tion and subclinical CV disease in Hispanic or Asian
subjects. Third, our serum TnI and BNP samples
were acquired the morning before anthracycline
administration; therefore, the results and conclusions
related to chronic TnI elevation observed in this
study may differ from those that are recognized
within hours after anthracycline administration.
Larger elevations in serum TnI have been observed
in children immediately after receipt of an anthra-
cycline (32).
CONCLUS IONS
Independent of gender, age, black or white race, and
the number of CV risk factors, cardiac systolic per-
formance declined and aortic stiffness increased
early after exposure to low to moderate doses of
anthracycline-based chemotherapeutic regimens for
these study patients with breast cancer or a hemato-
logic malignancy. These data indicate that low-dose
Anth-bC is associated with subclinical abnormal-
ities of CV function that in other high-risk pop-
ulations are associated with CV events. Further
investigations are warranted to determine if these
markers of subclinical CV disease that develop early
after anthracycline administration are associated with
future CV events in cancer survivors.Acknowledgment
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